Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. 3-dimensional spherical nucleic acid (snaâ„) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. lead programs address diseases from inflammatory disorders to oncology. sna constructs display unparalleled transfection efficiency in numerous cell and tissue types including skin without carriers or transfection agents.